|
Jun 13
|
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
|
|
Feb 26
|
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
|
|
Nov 29
|
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
|
|
Nov 27
|
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
|
|
Aug 25
|
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
|
|
Jul 5
|
Ceapro to Participate in the Virtual Investor Summer Spotlight Series
|
|
Apr 27
|
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
|